Stereotactic body radiotherapy safe, effective for low to intermediate risk prostate cancer
Stereotactic body radiotherapy induced high rates of biochemical control and low rates of severe toxicity among men with low- or... Read More
Use of Conservative Management for Low-Risk Prostate Cancer ‘Increasing Rapidly’
Conservative management or deferred treatment is the preferred approach for men with low-risk prostate cancer, according to results of a... Read More
Nearly 10% of Patients with Prostate Cancer Lost to Follow Up
Almost one in 10 patients with prostate cancer who were under active surveillance were lost to follow up, according to... Read More
Studies of Immunotherapy for Prostate Cancer Yield Encouraging Results
Several studies designed to investigate immunotherapies and immunotherapeutic combinations for treatment of prostate cancer have yielded encouraging results. “Thus far,... Read More
Finasteride Does Not Increase Risk for Prostate Cancer Death
Previously, the Prostate Cancer Prevention Trial showed finasteride increased the number of high-grade prostate cancers, even as it reduced patients’ overall... Read More
FDA Approves Yonsa for Metastatic Castration-Resistant Prostate Cancer
The FDA approved a novel formulation of abiraterone acetate in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant... Read More
MRI-Based Prediction Model May Reduce Unnecessary Biopsies in Prostate Cancer
Including MRI-derived parameters in a prediction model reduced the number of unnecessary biopsies while still detecting a high rate of... Read More
Greater Ejaculation Frequency May Reduce Prostate Cancer Risk
Ten-year follow-up data from a prospective cohort study add to prior evidence that suggested more frequent ejaculation may reduce prostate... Read More
Prostate Cancer Screening Rates Vary Significantly by State
Adherence to the U.S. Preventive Services Task Force 2011 recommendations on PSA screening differed significantly from state to state, according... Read More
Metastasis-Free Survival Viable Endpoint for Prostate Cancer Trials
Metastasis-free survival could be a surrogate endpoint for OS in clinical trials designed to evaluate adjuvant therapy options for patients... Read More